Chief Executive Pascal Soriot has driven a change in the company’s fortunes by investing in varied products and betting on newer medicines, which jolted the drugmaker onto the global stage. The company reiterated it was on track with late-stage trials for its coronavirus vaccine. Newer drugs for diabetes, heart conditions and cancer, including its top selling lung cancer drug Tagrisso, performed well in the quarter and AstraZeneca remains on track for a third consecutive year of growth in sales. …read more
Source:: Yahoo Finance
